Our Strategy
1
To make our lead product Feraccru® / Accrufer® (Ferric Maltol) available to as many patients as possible in collaboration with commercial partners
2
Effectively use clinical and pharmaco-economic data to support commercial partners
3
Engage with a well-resourced and ambitious partner to enable commercial success in the US market for Accrufer®
4
Establish Feraccru® / Accrufer® (Ferric Maltol) as the first choice for patients who have failed salt-based oral iron treatment
5
To maintain a scalable supportive infrastructure that facilitates product development and commercial success
6
To evaluate opportunities to out-licence PT20 to an attractive commercial partner